Holmium-166 SIRT Scout Dose QuiremScout Awarded Top 3 Most Innovative Medical Device in the 2019 Belgian Galenus Prize

LEUVEN, BELGIUM - December 9, 2020 - Terumo Europe N.V. is awarded top 3 innovative medical device in the 2019 Belgian Galenus prize with the innovative Holmium-166 SIRT diagnostic scout dose product QuiremScout™.

The Galenus prize recognizes and rewards outstanding achievements that improve the global human condition through the development of innovative therapies¹. It was created in France in 1970 by a pharmacist named Roland Mehl with the aim to advance pharmaceutical research. Recently, the Prix Galien award is also granted to innovative medical devices².

The role of QuiremScout microspheres is to evaluate the expected safety and efficacy of the Selective Internal Radiation Therapy (SIRT). QuiremScout microspheres are based on the same Holmium-166 microspheres as the therapeutic treatment (QuiremSpheres™). QuiremScout microspheres are intended to evaluate lung-shunt³ and extrahepatic deposition³ as part of the SIRT work-up. Moreover, they are intended for evaluation of the intrahepatic distribution³ during the work-up, which can be used to plan the SIRT treatment⁴.

Currently, ^99mTc-MAA is most often used during the pre-treatment work-up of the SIRT treatment algorithm⁴.

However, QuiremScout has recently proven to be more accurate in terms of intrahepatic targeting⁵ and lung shunt assessment⁶ compared to ^99mTc-MAA during the work-up. The usage of QuiremScout microspheres may allow physicians to improve their SIRT treatment planning⁴.

Recent clinical results continue to support the validation of QuiremScout microspheres in patient selection and planning as part of the Holmium Platform, such as the latest publication in the Lancet Oncology Journal from UMC Utrecht for the non-randomized HEPAR PLuS study⁷, which included Neuroendocrine tumor (NET) patients with liver metastasis after systemic radiation therapy with ¹⁷⁷Lu-Dotatate.

The Holmium platform consists of three integrated products (QuiremScout, QuiremSpheres & Q-suite™), which equips physicians with the necessary tools to optimize SIRT outcomes through more individualized treatment.

"QuiremScout is part of the Holmium platform that enables physicians to perform Selective intra-arterial radiation therapy. This technology uniquely allows a fine patient selection and individualized treatment for better outcomes. At Terumo, we are proud of this important recognition by the community.", said Laurent Domas, Vice President Global Interventional Oncology & Therapy Development, Terumo Interventional Systems.

Terumo has completed the acquisition of Quirem Medical B.V., a Netherlands-based healthcare startup specializing in the development of next-generation microspheres for Selective Internal Radiation Therapy (SIRT), a treatment for liver tumors.

About Terumo Europe

Terumo Europe, founded in 1971, is a core player in the EMEA healthcare market by providing best in class quality medical products and services. We are a strong actor of the Terumo Group by contributing to innovation and sustainable growth. Terumo Europe produces, distributes, markets and sells a vast range of medical devices in four main business units: Hospital and Laboratory Systems, Global Pharmaceutical Solutions, Interventional Systems and CardioVascular Products. Terumo Europe EMEA headquarters and production facilities are located in Haasrode (Belgium), production facility in Knowsley (UK) and sales units across EMEA.

Please visit www.terumo-europe.com for more information.

• *1

  https://www.prixgalien.nl/

• *2

  http://www.prixgalien-galenusprijs.be/

• *3

  Instructions for Use- QuiremScout (rev 05)

• *4

  Chiesa & Maccauro, 2020 EJNMM

• *5

  Smits et al., 2019 EJNMM

• *6

  Elschot et al., 2014 EJNMM

• *7

  Braat et. Al. 2020, Lancet Oncology